Enzo Biochem Inc. (ENZ) Reaches New 1-Year High at $7.00
Shares of Enzo Biochem Inc. (NYSE:ENZ) hit a new 52-week high on Friday . The company traded as high as $7.00 and last traded at $6.94, with a volume of 246,252 shares traded. The stock had previously closed at $6.70.
Separately, Zacks Investment Research raised shares of Enzo Biochem from a “hold” rating to a “buy” rating and set a $6.25 price target for the company in a report on Thursday, June 16th.
The company has a market capitalization of $322.46 million and a price-to-earnings ratio of 18.25. The company’s 50-day moving average is $6.10 and its 200 day moving average is $5.22.
Enzo Biochem (NYSE:ENZ) last posted its quarterly earnings data on Wednesday, June 8th. The company reported ($0.04) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.06) by $0.02. During the same quarter last year, the business posted ($0.07) EPS. The company had revenue of $18.16 million for the quarter, compared to analysts’ expectations of $24.50 million. On average, analysts expect that Enzo Biochem Inc. will post ($0.23) earnings per share for the current year.
Enzo Biochem, Inc (Enzo) is an integrated life science and biotechnology company, which is engaged in the research, development, manufacturing and marketing of diagnostic and research products based on genetic engineering, biotechnology and molecular biology. These products are designed for the diagnosis of and/or screening for infectious diseases, cancers, genetic defects and other medically pertinent diagnostic information and are distributed in the United States and internationally.
Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.